Numinus Wellness Inc., a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce Cedar Clinical Research is a top research site for MindMed’s Phase 2b study evaluating MM-120 for General Anxiety Disorder.

This is sponsored content issued on behalf of Numinus Wellness, please see full disclaimer here.

More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.